BiotechTube

Bimatoprost Sustained Release Implant

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open-angle Glaucoma

Conditions

Open-angle Glaucoma

Trial Timeline

— → —

NCT ID
NCT05338606

About Bimatoprost Sustained Release Implant

Bimatoprost Sustained Release Implant is a pre-clinical stage product being developed by AbbVie for Open-angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05338606. Target conditions include Open-angle Glaucoma.

What happened to similar drugs?

5 of 19 similar drugs in Open-angle Glaucoma were approved

Approved (5) Terminated (1) Active (13)
🔄Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
🔄A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
🔄Bimatoprost SRAbbViePhase 3
🔄Bimatoprost SR + LUMIGANAbbViePhase 3
🔄Bimatoprost (SR)AbbViePhase 3
🔄Bimatoprost SR + Sham Bimatoprost SRAbbViePhase 3
🔄Preservative-Free Tafluprost + Comparator: timololMerckPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05338606Pre-clinicalCompleted

Competing Products

20 competing products in Open-angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
DE-104 ophthalmic solution + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicleSanten PharmaceuticalPhase 2
35
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Bimatoprost SRAbbViePhase 3
44
Bimatoprost SR + LUMIGANAbbViePhase 3
40
AGN-193408 SR + AGN-193408 SRAbbViePhase 1/2
39
Bimatoprost (SR)AbbViePhase 3
40
Bimatoprost SR + Sham Bimatoprost SRAbbViePhase 3
40
Preservative-Free Tafluprost + Comparator: timololMerckPhase 3
40
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved
43
Placebo + RO5093151RochePhase 2
35
0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005%RochePhase 1
29
XalacomPfizerPhase 3
40
XalatanPfizerPhase 2
27
LatanoprostPfizerApproved
43
PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - VehiclePfizerPhase 2
35
XalacomPfizerPre-clinical
26
Xalacom + Xalatan + TimololPfizerPhase 3
40
PF-04217329 + latanoprost vehicle + PF-04217329 + latanoprostPfizerPhase 2
35